- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06349408
IBI3001 bij deelnemers met inoperabele, lokaal gevorderde of gemetastaseerde solide tumoren
Een fase 1/2-onderzoek naar IBI3001 bij deelnemers met inoperabele, lokaal gevorderde of gemetastaseerde solide tumoren
This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
Studie Locaties
-
-
New South Wales
-
Wollongong, New South Wales, Australië, 2500
- Werving
- Wollongong Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
South Australia
-
Adelaide, South Australia, Australië, 5000
- Werving
- Cancer Research SA
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
-
-
Anhui
-
Hefei, Anhui, China, 230022
- Werving
- The First Affiliated Hospital of Anhui Medical University
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100021
- Werving
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Beijing, Beijing Municipality, China, 100853
- Werving
- Chinese People's Liberation Army General Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Werving
- Fujian Cancer Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Fuzhou, Fujian, China, 350005
- Werving
- First Affiliated Hospital, Fujian Medical University
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- Werving
- The Affiliated Tumor Hospital of Guangxi Medical University
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Werving
- Harbin Medical University Cancer Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Henan
-
Anyang, Henan, China, 455100
- Werving
- Anyang Cancer Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Luoyang, Henan, China, 471003
- Werving
- The First Affiliated Hospital of Henan University of Science and Technology
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Zhengzhou, Henan, China, 450008
- Werving
- Henan Cancer Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Zhengzhou, Henan, China, 450052
- Werving
- The First Affiliated Hospital of Zhengzhou University
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Werving
- Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Werving
- Xiangya Hospital, Central South University
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Werving
- Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Nanjing, Jiangsu, China, 210029
- Werving
- Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University)
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330029
- Werving
- Jiangxi Cancer Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200120
- Werving
- Shanghai East Hospital, Tongji University School of Medicine
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Werving
- West China Hospital, Sichuan University
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Chengdu, Sichuan, China, 610041
- Werving
- Sichuan Cancer Hospital & Institute
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Werving
- Zhejiang Cancer Hospital
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
Hangzhou, Zhejiang, China, 310003
- Werving
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
-
-
California
-
Los Angeles, California, Verenigde Staten, 90025
- Werving
- START Center for Cancer Research
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
New Jersey
-
East Brunswick, New Jersey, Verenigde Staten, 08816
- Werving
- START Center for Cancer Research
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75039
- Werving
- NEXT Oncology
-
Contact:
- Fortvita Biologics CT.gov Call Center
- Telefoonnummer: 650-370-0985
- E-mail: ct.govNotifications@fortvitabio.com
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Actief, niet wervend
- Virginia Cancer Specialists
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
- Male or female participants ≥ 18 years old;
- Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
- Has an anticipated life expectancy of ≥ 12 weeks;
- Adequate bone marrow and organ function:
- At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. for dose escalation , and 1 measurable lesion for dose expansion.
- Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; participants who refuse standard therapy, or are able to suspend standard therapy without major risks.
Key Exclusion Criteria:
- Progressed or refractory to an ADC that consists of an Exatecan derivative that is a topoisomerase I inhibitor or intolerable with an ADC that consists of Exatecan;
- Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also not have an impact on tumor assessment throughout the study;
- Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours);
- Gastrointestinal perforation and/or fistula within 6 months prior to first administration of the study drug, and not recovered after surgical treatment;
- Known symptomatic central nervous system (CNS) metastases.
- History of pneumonia requiring corticosteroids therapy, or history of clinically significant lung diseases; Uncontrolled diseases;
- History of endotracheal or gastrointestinal stent implantation;
- Ascites, pleural effusion, or pericardial effusion with symptoms and requiring intervention;
- Esophageal or gastric varices requiring immediate intervention;
- Not eligible to participate in this study at the discretion of the investigator;
- Do not have adequate treatment washout period before study drug administration. -
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Open-label: IBI3001 monotherapie
|
The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study. IBI3001 is proposed to be administered by intravenous infusion (IV) |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of subjects with adverse events
Tijdsspanne: 24 months
|
Occurrence and severity of adverse events (AEs), with severity determined by NCI CTCAE v5.0 criteria |
24 months
|
|
Number of subjects with clinically significant changes in physical examination results
Tijdsspanne: 24 months
|
Clinically significant abnormal physical examination findings reported by the investigator. |
24 months
|
|
Number of subjects with clinically significant changes in vital signs
Tijdsspanne: 24 months
|
Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure |
24 months
|
|
MTD or RP2D of IBI3001 Number of subjects with dose-limiting toxicities (DLTs)
Tijdsspanne: 24 months
|
Dose limiting toxicity (DLT) to establish MTD or RP2D |
24 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Plasma concentration (Cmax) of IBI3001
Tijdsspanne: 24 months
|
Plasma concentration of IBI3001 for single and multiple doses. |
24 months
|
|
Area under the curve (AUC) of IBI3001
Tijdsspanne: 24 months
|
AUC of IBI3001 for single and multiple doses |
24 months
|
|
Time to maximum concentration (Tmax) of IBI3001
Tijdsspanne: 24 months
|
Tmax of IBI3001 for single and multiple doses. |
24 months
|
|
Clearance (CL) of IBI3001
Tijdsspanne: 24 months
|
Clearance of IBI3001 from the plasma |
24 months
|
|
Volume of distribution (V) of IBI3001
Tijdsspanne: 24 months
|
Apparent volume of distribution of IBI3001 |
24 months
|
|
Half-life (T1/2) of IBI3001
Tijdsspanne: 24 months
|
T1/2 of IBI3001 for single and multiple doses |
24 months
|
|
Immunogenicity of IBI3001
Tijdsspanne: 24 months
|
Incidence of anti-drug (IBI3001) antibody |
24 months
|
|
Objective response rate (ORR)
Tijdsspanne: 24 months
|
ORR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Duration of response (DoR)
Tijdsspanne: 24 months
|
DoR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Disease control rate (DCR)
Tijdsspanne: 24 months
|
DCR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Time to response (TTR)
Tijdsspanne: 24 months
|
TTR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Progression free survival (PFS)
Tijdsspanne: 24 months
|
PFS as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Overall survival (OS)
Tijdsspanne: 24 months
|
Overall survival. |
24 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- CIBI3001A101
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .